Duplex Sequencing in MutaMouse at Labcorp: A pilot trial

UKEMS 2024 -- Error-corrected next generation sequencing (ecNGS) is an emergent technology that enables the quantification of low-frequency mutations by significantly reducing the occurrence of artificial replication errors for mutation frequency assessment. It is also a powerful tool in qualifying modal mechanisms underlying mutations, aiding with compound classification. This has become of key interest within the field of genetic toxicology for its potential applications to transgenic rodent studies (TGR), integration onto general toxicology studies and beyond. At Labcorp, we have extensive experience in performing the MutaMouse transgenic rodent assay, along with integrating genetic toxicology endpoints onto general toxicology studies for investigative and regulatory submission. Active collaboration between US and UK OECD representatives has been announced to incorporate ecNGS into existing appropriate Test Guidelines. In this pilot trial, Labcorp partnered with TwinStrand Biosciences to sequence, via Duplex Sequencing, MutaMouse DNA samples obtained from liver and bone marrow tissues.